The Fleischner Society pulmonary nodule recommendations pertain to the follow-up and management of indeterminate pulmonary nodules detected incidentally on CT and are published by the Fleischner Society. The guideline does not apply to lung cance…
ASCO’s Virtual Mentoring Program pairs members with a mentor outside of their institution to address unmet career development needs of practicing oncologists, populations underrepresented in
This program targets trainees wanting to further their palliative care skills to be able to deliver high-quality cancer care with palliative/supportive care integrated across the…
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly devel…
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly devel…
Falchi and colleagues review the development of and clinical experience with bispecific antibodies, a class of T-cell redirecting drugs with excellent activity
Original Article from The New England Journal of Medicine — Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.
Background: The treatment of follicular lymphoma (FL) has previously centered on chemoimmunotherapy, which can be disadvantageous due to patient intolerance, cumulative toxicities, and disease refractoriness.…
